Variant position: 688 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 795 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human APGIGPISFPEAQEG---LMGIG RRPFSQGLQQMMDHEARLLVA
Mouse APSIGPVSFPEAQEG---LMGIG RRPFSQGLQQMMDHEAKL
Rat APSIGPVSFPEAQEG---LVGIG RRPFSQGLQQMMDHEARL
Slime mold SSETQPPITPPPTTGTSCLAQVQ QKVINSWINGEVDHYIQV
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
106 – 795 Paraplegin
270 – 795 Mitochondrial matrix
490 – 795 Missing. In isoform 2.
Mutation analysis of the paraplegin gene (SPG7) in patients with hereditary spastic paraplegia.
Elleuch N.; Depienne C.; Benomar A.; Hernandez A.M.; Ferrer X.; Fontaine B.; Grid D.; Tallaksen C.M.E.; Zemmouri R.; Stevanin G.; Durr A.; Brice A.;
Cited for: VARIANTS SPG7 VAL-510 AND VAL-581 DEL; VARIANTS THR-2; GLN-82 DEL; PRO-284; HIS-294; GLN-486 ALA-503; LEU-545; THR-603; LEU-635; THR-645; HIS-650; GLN-688 AND ASP-730;
Functional evaluation of paraplegin mutations by a yeast complementation assay.
Bonn F.; Pantakani K.; Shoukier M.; Langer T.; Mannan A.U.;
Hum. Mutat. 31:617-621(2010)
Cited for: VARIANTS SPG7 SER-349; VAL-510 AND CYS-583; VARIANTS ALA-503 AND GLN-688; CHARACTERIZATION OF VARIANTS SPG7 SER-349; VAL-510 AND CYS-583; CHARACTERIZATION OF VARIANTS ALA-503 AND GLN-688;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.